TY - JOUR
T1 - Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma
AU - Kahana-Edwin, Smadar
AU - McCowage, Geoffrey
AU - Cain, Lucy
AU - Saletta, Federica
AU - Yuksel, Aysen
AU - Graf, Nicole
AU - Karpelowsky, Jonathan
PY - 2020
Y1 - 2020
N2 - Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.
AB - Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.
UR - https://hdl.handle.net/1959.7/uws:66526
U2 - 10.1002/pbc.28594
DO - 10.1002/pbc.28594
M3 - Article
SN - 1545-5009
VL - 67
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 11
M1 - e28594
ER -
